ClinicalTrials.gg
CompletedNCT05407064Updated Feb 27, 2026Results posted

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

A Phase 2 interventional study of MM120 and Placebo in Anxiety Generalized, sponsored by Definium Therapeutics US, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
78th of 234
198 · median 90
Started
2022
with 10 others
Phase 2
21 of 265
5 open now
Registered
206th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 78th largest by enrollment of the 234 interventional ones that give a count, is one of 11 that started in 2022, is one of 21 in phase 2, and was the 206th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Read the detailed description

The study will enroll approximately 200 male and female subjects 18 years to \< 75 years of age who meet DSM-5 criteria for GAD and have a minimum HAM-A Total Score of 20. Subjects on contraindicated concomitant medications, supplements or other therapeutics at Screening (Visit 1) will undergo a medication taper prior to advancing to Baseline (Visit 2).

03

Conditions studied

  • Anxiety Generalized
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bodyweight of ≥ 50 kg
  • [BMI] ≥ 18 to ≤ 38 mg/kg2
  • Diagnosis of generalized anxiety disorder
  • Acceptable overall medical condition to be safely enrolled into and to complete the study
  • Ability to swallow capsules
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Women of (WOCBP) (i.e., physiologically capable of becoming pregnant) who are unwilling or unable to use a highly effective method of for the duration of the study, OR Men physiologically capable of fathering a child who are sexually active with WOCBP but are unwilling or unable to use barrier contraception (e.g., condom with or without spermicidal cream or jelly) for the duration of the study
  • Women who are currently pregnant or breastfeeding or plan to become pregnant or breastfeed during the study
  • Men who plan to donate sperm during the study
  • Prior history (lifetime diagnosis) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorders or bipolar disorder
  • Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation
  • Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (actual)

Study arms

  • Placebo comparator
    Arm 1- Placebo

    A substance that is designed to have no therapeutic value.

    Other: Placebo

  • Experimental
    Arm 2- 25 μg MM120

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

    Drug: MM120

  • Experimental
    Arm 3- 50 μg MM120

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

    Drug: MM120

  • Experimental
    Arm 4- 100 μg MM120

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

    Drug: MM120

  • Experimental
    Arm 5- 200 μg MM120

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

    Drug: MM120

Interventions

  • DrugMM120

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

    Also known as: MM-120, DT120, lysergide tartrate

  • OtherPlacebo

    A substance that is designed to have no therapeutic value.

06

What researchers measure

Primary outcomes

  1. Dose Response

    To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.

    Time frame: 4 weeks

Secondary outcomes

  1. Dose Response

    To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 8. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.

    Time frame: 8 weeks

  2. Change From Baseline in HAM-A Total Score

    To determine the change from Baseline of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared to Placebo as measured by the change in HAM-A Total Score from Baseline to Week 4 Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 4

    Time frame: 4 weeks

  3. Change From Baseline in HAM-A Total Scores

    To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to Week 8. Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 8

    Time frame: 8 weeks

  4. Change From Baseline in HAM-A Total Scores

    To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to End of Study (Week 12). Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to end of study (12 weeks)

    Time frame: 12 weeks

  5. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms as measured by the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

    Time frame: Week 1

  6. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

    Time frame: Week 2

  7. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

    Time frame: Week 4

  8. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

    Time frame: Week 8

  9. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

    Time frame: End of Study (Week 12)

  10. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

    Time frame: Week 1

  11. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

    Time frame: Week 2

  12. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

    Time frame: Week 4

  13. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

    Time frame: Week 8

  14. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

    Time frame: End of Study (12 weeks)

  15. Mean Clinical Global Impression - Improvement (CGI-I) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

    Time frame: Week 1

  16. Mean Clinical Global Impression - Improvement (CGI-I) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

    Time frame: Week 2

  17. Mean Clinical Global Impression - Improvement (CGI-I) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

    Time frame: Week 4

  18. Mean Clinical Global Impression - Improvement (CGI-I) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7).

    Time frame: Week 8

  19. Mean Clinical Global Impression - Improvement (CGI-I) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

    Time frame: End of Study (Week 12)

  20. Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

    Time frame: Week 1

  21. Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

    Time frame: Week 2

  22. Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

    Time frame: Week 4

  23. Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

    Time frame: Week 8

  24. Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

    Time frame: End of study (Week 12)

  25. Mean Patient Global Impression - Change (PGI-C) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

    Time frame: Week 1

  26. Mean Patient Global Impression - Change (PGI-C) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

    Time frame: Week 2

  27. Mean Patient Global Impression - Change (PGI-C) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

    Time frame: Week 4

  28. Mean Patient Global Impression - Change (PGI-C) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

    Time frame: Week 8

  29. Change From Baseline in Patient Global Impression - Change (PGI-C) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

    Time frame: End of Study (Week 12)

  30. Change From Baseline in Sheehan Disability Scale (SDS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

    Time frame: Week 1

  31. Change From Baseline in Sheehan Disability Scale (SDS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

    Time frame: Week 2

  32. Change From Baseline in Sheehan Disability Scale (SDS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

    Time frame: Week 4

  33. Change From Baseline in Sheehan Disability Scale (SDS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

    Time frame: Week 8

  34. Change From Baseline in Sheehan Disability Scale (SDS) Total Scores

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

    Time frame: End of Study (Week 12)

  35. Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

    Time frame: Week 1

  36. Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

    Time frame: Week 2

  37. Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

    Time frame: Week 4

  38. Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

    Time frame: Week 8

  39. Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

    Time frame: End of Study (12 weeks)

  40. Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

    Time frame: Week 4

  41. Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

    Time frame: Week 8

  42. Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

    Time frame: End of Study (Week 12)

  43. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 1

  44. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 2

  45. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 4

  46. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 8

  47. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: End of Study (Week 12)

  48. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 1

  49. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 2

  50. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 4

  51. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 8

  52. Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

    To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: End of Study (Week 12)

  53. Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 1

    Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 1

  54. Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 2

    Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 2

  55. Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 4

    Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 4

  56. Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 8

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 8

  57. Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 12

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: End of Study (Week 12)

  58. Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 1

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 1

  59. Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 2

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 2

  60. Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 4

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 4

  61. Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 8

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 8

  62. Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 12

    Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

    Time frame: Week 12

07

Results

Posted Mar 20, 2025
Limitations and caveats
DSMs assisted and monitored participants which could be construed to have an independent therapeutic effect. So, DSMs were given training to not engage in psychotherapy with participants. There was a potential for unblinding so blinded independent central raters assessed the primary efficacy outcome.

Participant flow

A total of 554 potential participants were screened and 356 were excluded. Of the 198 participants randomized to study treatment, 147 (74.2%) completed the study.

Participant flow — Overall Study
MilestoneArm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120
Started3939404040
Completed2629293330
Not completed131011710

Outcome measures

PrimaryDose Response

To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Dose Response
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method-14.23 (-17.83 to -10.63)-15.35 (-17.62 to -13.09)-16.05 (-19.40 to -12.71)-19.22 (-21.73 to -16.70)-20.09 (-22.87 to -17.31)
Mean Difference in HAM-A total score from Placebo0.0 (0.0 to 0.0)-1.24 (-6.01 to 3.53)-1.82 (-7.65 to 4.00)-5.02 (-9.60 to -0.44)-5.95 (-9.84 to -2.06)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) ·
SecondaryDose Response

To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 8. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.

Time frame:
8 weeks
Reported as:
Mean · units on a scale
Dose Response
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Mean change from Baseline to Week 8 HAM-A total score from Model Averaging Method-15.51 (-17.79 to -13.23)-16.24 (-18.12 to -14.36)-16.90 (-18.70 to -15.09)-18.39 (-20.17 to -16.61)-20.94 (-23.92 to -17.95)
Mean difference from Placebo at Week 80.0 (0 to 0)-0.76 (-1.72 to 0.20)-1.44 (-3.08 to 0.20)-2.92 (-5.37 to -0.46)-5.43 (-9.46 to -1.39)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) ·
SecondaryChange From Baseline in HAM-A Total Score

To determine the change from Baseline of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared to Placebo as measured by the change in HAM-A Total Score from Baseline to Week 4 Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 4

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in HAM-A Total Score-13.6 ± 9.79-17.2 ± 10.53-14.8 ± 9.96-20.9 ± 9.72-19.7 ± 9.48
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.1157
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.6630
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0004
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0100
SecondaryChange From Baseline in HAM-A Total Scores

To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to Week 8. Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 8

Time frame:
8 weeks
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in HAM-A Total Scores-15.4 ± 9.72-18.6 ± 10.91-14.5 ± 10.15-19.4 ± 10.28-21.1 ± 10.37
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.2309
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.7218
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0637
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0216
SecondaryChange From Baseline in HAM-A Total Scores

To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to End of Study (Week 12). Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to end of study (12 weeks)

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in HAM-A Total Scores-14.3 ± 11.95-18.7 ± 10.85-17.3 ± 10.71-21.1 ± 10.35-22.0 ± 11.85
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.1006
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.2225
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0025
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · ANCOVA · p = 0.0042
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms as measured by the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

Time frame:
Week 1
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores-11.0 ± 11.62-12.3 ± 10.45-11.1 ± 10.59-17.6 ± 11.21-17.4 ± 10.66
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.6258
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.95
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0174
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0206
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

Time frame:
Week 2
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores-11.0 ± 11.59-12.7 ± 12.36-12.2 ± 10.50-17.3 ± 11.0-18.8 ± 10.33
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.5538
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.6650
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0190
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0034
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

Time frame:
Week 4
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores-12.4 ± 9.96-11.4 ± 11.63-12.3 ± 10.99-18.1 ± 11.97-18.3 ± 11.69
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.7236
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.9738
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0338
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0282
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores-12.2 ± 9.63-12.5 ± 11.88-11.1 ± 11.59-17.2 ± 12.66-18.6 ± 10.84
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.9302
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.6763
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0816
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0190
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores-12.3 ± 9.53-13.9 ± 11.29-14.6 ± 8.57-18.7 ± 11.47-19.9 ± 11.15
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.5647
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.3497
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0229
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0073
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

Time frame:
Week 1
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
change from Baseline-1.0 (-1.46 to -0.54)-1.8 (-2.18 to -1.34)-1.7 (-2.20 to -1.19)-2.3 (-2.67 to -1.85)-2.4 (-2.80 to -1.97)
Difference in means (MM120-placebo)0 (0 to 0)-0.76 (-1.38 to -0.15)-0.69 (-1.37 to -0.02)-1.26 (-1.87 to -0.66)-1.39 (-2.00 to -0.78)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0158
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0429
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0001
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

Time frame:
Week 2
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
change from baseline-1.1 (-1.61 to -0.67)-1.7 (-2.16 to -1.26)-1.8 (-2.35 to -1.30)-2.4 (-2.81 to -1.98)-2.5 (-2.89 to -2.14)
Difference in means (MM120-placebo)0 (0 to 0)-0.57 (-1.21 to 0.07)-0.68 (-1.38 to 0.01)-1.26 (-1.87 to -0.64)-1.37 (-1.97 to -0.78)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0804
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0532
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0001
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

Time frame:
Week 4
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.3 (-1.85 to -0.79)-1.8 (-2.25 to -1.28)-1.7 (-2.12 to -1.19)-2.5 (-2.93 to -2.05)-2.3 (-2.74 to -1.88)
Difference in means (MM120-placebo)0 (0 to 0)-0.44 (-1.15 to 0.26)-0.33 (-1.03 to 0.36)-1.16 (-1.84 to -0.49)-0.99 (-1.65 to -0.32)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2152
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.3369
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0010
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0046
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.5 (-2.15 to -0.88)-1.8 (-2.28 to -1.34)-1.7 (-2.18 to -1.13)-2.3 (-2.74 to -1.83)-2.5 (-2.99 to -2.04)
Difference in means (MM120-placebo)0 (0 to 0)-0.29 (-1.07 to 0.48)-0.14 (-0.94 to 0.67)-0.77 (-1.53 to 0.00)-1.00 (-1.77 to -0.22)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.4489
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.7326
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0492
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0131
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)

Time frame:
End of Study (12 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.4 (-2.08 to -0.77)-1.8 (-2.37 to -1.29)-2.1 (-2.59 to -1.55)-2.6 (-3.02 to -2.19)-2.5 (-3.08 to -1.95)
Difference in means (MM120-placebo)0 (0 to 0)-0.40 (-1.24 to 0.43)-0.65 (-1.46 to 0.17)-1.18 (-1.95 to -0.42)-1.09 (-1.94 to -0.24)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.3330
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1193
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0032
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0127
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

Time frame:
Week 1
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual Values CGI-I3.1 (2.69 to 3.49)2.4 (2.07 to 2.67)2.3 (1.98 to 2.69)1.8 (1.55 to 2.03)1.9 (1.61 to 2.16)
Difference in means (MM120-placebo)0 (0 to 0)-0.72 (-1.21 to -0.23)-0.75 (-1.28 to -0.23)-1.30 (-1.76 to -0.84)-1.20 (-1.68 to -0.73)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0046
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0052
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

Time frame:
Week 2
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values (CGI-I scores)3.0 (2.62 to 3.44)2.5 (2.13 to 2.87)2.4 (1.92 to 2.78)1.7 (1.43 to 1.94)1.9 (1.67 to 2.17)
Difference in means (MM120-placebo)0 (0 to 0)-0.53 (-1.07 to 0.02)-0.67 (-1.26 to -0.09)-1.34 (-1.82 to -0.87)-1.11 (-1.58 to -0.64)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0567
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0235
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

Time frame:
Week 4
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual value (CGI-I score)2.8 (2.27 to 3.28)2.4 (2.00 to 2.82)2.4 (1.99 to 2.86)1.8 (1.51 to 2.08)2.2 (1.76 to 2.55)
Difference in Means (MM120-placebo)0 (0 to 0)-.036 (-1.00 to 0.28)-0.35 (-1.00 to 0.31)-0.98 (-1.56 to -0.40)-0.62 (-1.25 to 0.01)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2632
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2962
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0013
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0547
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7).

Time frame:
Week 8
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual vaues (CGI-I scores)2.7 (2.23 to 3.25)2.2 (1.86 to 2.58)2.7 (2.08 to 3.23)1.8 (1.51 to 2.15)2.0 (1.63 to 2.31)
Difference in means (MM120-placebo)0 (0 to 0)-0.52 (-1.14 to 0.09)-0.08 (-0.84 to 0.67)-0.91 (-1.50 to -0.32)-0.77 (-1.37 to -0.17)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0937
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.8230
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0032
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0129
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values (CGI-I scores)2.7 (2.19 to 3.27)2.3 (1.96 to 2.66)2.2 (1.68 to 2.73)1.6 (1.34 to 1.93)1.9 (1.46 to 2.35)
Difference in means (MM120-placebo)0 (0 to 0)-0.42 (-1.06 to 0.21)-0.52 (-1.26 to 0.21)-1.09 (-1.70 to -0.49)-0.83 (-1.52 to -0.14)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1889
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1589
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0008
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0194
SecondaryChange From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

Time frame:
Week 1
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-0.7 (-0.98 to -0.43)-1.3 (-1.55 to -0.98)-1.2 (-1.55 to -0.90)-1.6 (-1.84 to -1.27)-1.6 (-1.91 to -1.32)
Difference in means (MM120-placebo)0 (0 to 0)-0.56 (-0.95 to -0.17)-0.52 (-0.94 to -0.10)-0.85 (-1.24 to -0.46)-0.91 (-1.30 to -0.51)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0057
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0168
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
SecondaryChange From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

Time frame:
Week 2
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-0.8 (-1.10 to -0.45)-1.2 (-1.49 to -0.83)-1.3 (-1.65 to -0.88)-1.5 (-1.80 to -1.15)-1.6 (-1.88 to -1.26)
Difference in means (MM120-placebo)0 (0 to 0)-0.38 (-0.84 to 0.07)-0.49 (-0.98 to 0.01)-0.70 (-1.15 to -0.25)-0.79 (-1.23 to -0.35)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0958
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0544
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0029
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0006
SecondaryChange From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

Time frame:
Week 4
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.0 (-1.35 to -0.65)-1.3 (-1.70 to -0.95)-1.3 (-1.66 to -0.97)-1.5 (-1.78 to -1.19)-1.6 (-1.94 to -1.19)
Difference in means (MM120-placebo)0 (0 to 0)-0.32 (-0.83 to 0.18)-0.31 (-0.80 to 0.17)-0.49 (-0.94 to -0.03)-0.56 (-1.07 to -0.06)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2038
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1977
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0357
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0302
SecondaryChange From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.0 (-1.41 to -0.52)-1.3 (-1.67 to -0.95)-1.1 (-1.58 to -0.61)-1.4 (-1.70 to -1.05)-1.6 (-2.05 to -1.22)
difference in means (MM120-placebo)0 (0 to 0)-0.35 (-0.91 to 0.21)-0.13 (-0.78 to 0.52)-0.41 (-0.95 to 0.13)-0.67 (-1.27 to -0.08)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2165
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.6868
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1350
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0273
SecondaryChange From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)

Time frame:
End of study (Week 12)
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.1 (-1.57 to -0.58)-1.4 (-1.73 to -1.10)-1.4 (-1.80 to -0.96)-1.5 (-1.87 to -1.22)-1.5 (-1.86 to -1.04)
Difference in means (MM120-placebo)0 (0 to 0)-0.34 (-0.91 to 0.24)-0.30 (-0.94 to 0.34)-0.47 (-1.05 to 0.11)-0.37 (-1.01 to 0.26)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2450
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.3461
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1110
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.2386
SecondaryMean Patient Global Impression - Change (PGI-C) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

Time frame:
Week 1
Reported as:
Mean · units on a scale
Mean Patient Global Impression - Change (PGI-C) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual Values PGI-C2.3 (1.96 to 2.69)2.0 (1.74 to 2.26)1.8 (1.49 to 2.12)1.3 (1.14 to 1.55)1.5 (1.29 to 1.76)
Difference in means (MM120-placebo)0 (0 to 0)-0.32 (-0.76 to 0.12)-0.52 (-0.99 to -0.05)-0.98 (-1.39 to -0.57)-0.80 (-1.22 to -0.37)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1475
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0308
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0000
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0004
SecondaryMean Patient Global Impression - Change (PGI-C) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

Time frame:
Week 2
Reported as:
Mean · units on a scale
Mean Patient Global Impression - Change (PGI-C) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values PGI-C2.4 (2.01 to 2.72)1.9 (1.61 to 2.28)2.0 (1.61 to 2.39)1.6 (1.31 to 1.85)1.5 (1.20 to 1.72)
Difference in means (MM120-placebo)0 (0 to 0)-0.42 (-0.89 to 0.06)-0.36 (-0.88 to 0.16)-0.78 (-1.22 to -0.34)-0.90 (-1.33 to -0.47)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0873
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1702
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0007
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0001
SecondaryMean Patient Global Impression - Change (PGI-C) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

Time frame:
Week 4
Reported as:
Mean · units on a scale
Mean Patient Global Impression - Change (PGI-C) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values PGI-C2.3 (1.85 to 2.67)2.0 (1.63 to 2.43)1.9 (1.53 to 2.24)1.4 (1.17 to 1.55)1.7 (1.38 to 2.01)
Difference in means (MM120-placebo)0 (0 to 0)-0.23 (-0.79 to 0.33)-0.37 (-0.90 to 0.16)-0.90 (-1.35 to -0.45)-0.57 (-1.08 to -0.05)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.4193
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1663
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0002
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0306
SecondaryMean Patient Global Impression - Change (PGI-C) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

Time frame:
Week 8
Reported as:
Mean · units on a scale
Mean Patient Global Impression - Change (PGI-C) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values PGI-C2.1 (1.79 to 2.51)1.7 (1.46 to 1.98)2.0 (1.64 to 2.42)1.5 (1.27 to 1.81)1.8 (1.41 to 2.10)
Difference in means (MM120-placebo)0 (0 to 0)-0.43 (-0.87 to 0.01)-0.12 (-0.64 to 0.40)-0.61 (-1.04 to -0.17)-0.39 (-0.88 to 0.10)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0534
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.6551
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0079
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1133
SecondaryChange From Baseline in Patient Global Impression - Change (PGI-C) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Change From Baseline in Patient Global Impression - Change (PGI-C) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Actual values PGI-C2.2 (1.80 to 2.59)1.8 (1.56 to 2.10)1.8 (1.45 to 2.21)1.5 (1.25 to 1.72)1.7 (1.32 to 2.04)
Difference in means (MM120-placebo)0 (0 to 0)-0.36 (-0.83 to 0.10)-0.36 (-0.90 to 0.17)-0.71 (-1.16 to -0.25)-0.51 (-1.04 to 0.01)
Statistical analysis
  • Arm 1- Placebo vs Arm 2- 25 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1248
  • Arm 1- Placebo vs Arm 3- 50 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.1788
  • Arm 1- Placebo vs Arm 4- 100 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0030
  • Arm 1- Placebo vs Arm 5- 200 μg MM-120 (LSD D-Tartrate) · t-test, 2 sided · p = 0.0534
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

Time frame:
Week 1
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-7.4 (-10.00 to -4.83)-8.8 (-10.91 to -6.67)-8.0 (-10.73 to -5.33)-14.6 (-16.67 to -12.49)-13.6 (-15.61 to -11.59)
Difference in means (MM120-placebo)0 (0 to 0)-1.38 (-4.66 to 1.91)-0.62 (-4.29 to 3.05)-7.17 (-10.44 to -3.90)-6.19 (-9.40 to -2.97)
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

Time frame:
Week 2
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from Baseline-7.8 (-10.49 to -5.18)-9.8 (-12.32 to -7.30)-8.2 (-11.04 to -5.43)-14.0 (-16.23 to -11.71)-14.2 (-16.42 to -11.97)
Difference in means (MM120-placeb)0 (0 to 0)-1.98 (-5.57 to 1.61)-0.40 (-4.20 to 3.39)-6.14 (-9.57 to -2.71)-6.36 (-9.77 to -2.95)
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

Time frame:
Week 4
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-9.0 (-12.03 to -5.90)-9.5 (-12.24 to -6.67)-8.7 (-11.41 to -5.94)-14.9 (-17.18 to -12.66)-13.5 (-15.88 to -11.04)
Difference in means (MM120-placebo)0 (0 to 0)-0.49 (-4.55 to 3.58)0.29 (-3.74 to 4.32)-5.96 (-9.70 to -2.21)-4.49 (-8.33 to -0.66)
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-9.1 (-12.62 to -5.68)-10.5 (-13.21 to -7.73)-7.5 (-10.77 to -4.17)-13.8 (-16.48 to -11.18)-13.6 (-16.39 to -10.76)
Difference in means (MM120-placebo)0 (0 to 0)-1.32 (-5.65 to 3.01)1.68 (-3.01 to 6.37)-4.68 (-8.96 to -0.40)-4.43 (-8.81 to -0.05)
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Scores

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-8.2 (-11.75 to -4.65)-10.8 (-13.73 to -7.85)-9.0 (-12.52 to -5.54)-15.1 (-17.11 to -13.01)-13.1 (-15.88 to -10.37)
Difference in means (MM120-plcebo)0 (0 to 0)-2.59 (-7.10 to 1.91)-0.83 (-5.70 to 4.03)-6.86 (-10.89 to -2.83)-4.93 (-9.33 to -0.53)
SecondaryImproved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

Time frame:
Week 1
Reported as:
Mean · units on a scale
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline6.9 (1.08 to 12.69)11.2 (4.57 to 17.85)12.3 (7.15 to 17.46)15.7 (10.20 to 21.12)14.9 (9.79 to 19.93)
Difference in means (MM120-placebo)0 (0 to 0)4.33 (-4.34 to 13.00)5.43 (-2.20 to 13.05)8.78 (0.95 to 16.60)7.98 (0.41 to 15.55)
SecondaryImproved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

Time frame:
Week 2
Reported as:
Mean · units on a scale
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline10.3 (5.49 to 15.12)11.8 (4.66 to 18.85)10.6 (5.51 to 15.61)14.7 (9.72 to 19.64)15.9 (10.46 to 21.27)
Difference in means (MM120-placebo)0 (0 to 0)1.45 (-6.99 to 9.89)0.25 (-6.60 to 7.10)4.38 (-2.41 to 11.17)5.56 (-1.55 to 12.67)
SecondaryImproved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

Time frame:
Week 4
Reported as:
Mean · units on a scale
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline11.5 (5.79 to 17.17)13.5 (5.76 to 21.33)10.5 (4.76 to 16.33)15.5 (10.27 to 20.73)15.7 (9.02 to 22.32)
Difference in means (MM120-placebo)0 (0 to 0)2.03 (-7.41 to 11.53)-0.94 (-8.90 to 7.02)4.02 (-3.57 to 11.60)4.18 (-4.41 to 12.78)
SecondaryImproved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline10.8 (3.97 to 17.66)16.2 (10.20 to 22.18)9.7 (3.37 to 16.07)16.2 (9.94 to 22.52)17.0 (10.07 to 23.93)
Diference in means (MM120-placebo)0 (0 to 0)5.37 (-3.53 to 14.28)-1.10 (-10.23 to 8.04)5.41 (-3.69 to 14.52)6.19 (-3.35 to 15.72)
SecondaryImproved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.

Time frame:
End of Study (12 weeks)
Reported as:
Mean · units on a scale
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline11.7 (4.28 to 19.02)17.0 (9.92 to 24.01)13.2 (7.89 to 18.52)17.7 (12.85 to 22.55)17.3 (10.18 to 24.40)
Difference in means (MM120-placebo)0 (0 to 0)5.31 (-4.65 to 15.27)1.55 (-7.34 to 10.45)6.04 (-2.61 to 14.70)5.64 (-4.37 to 15.65)
SecondaryImproved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

Time frame:
Week 4
Reported as:
Mean · units on a scale
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-3.7 (-5.10 to -2.21)-3.8 (-5.20 to -2.37)-2.7 (-4.32 to -1.14)-5.3 (-6.57 to -4.01)-3.9 (-5.04 to -2.75)
Difference in means (MM120-placebo)0 (0 to 0)-0.13 (-2.11 to 1.86)0.93 (-1.18 to 3.04)-1.63 (-3.53 to 0.26)-0.24 (-2.05 to 1.57)
SecondaryImproved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-4.1 (-5.70 to -2.60)-5.4 (-6.97 to -3.80)-3.6 (-5.21 to -1.98)-5.1 (-6.61 to -3.67)-4.4 (-5.94 to -2.88)
Difference in means (MM120-placebo)0 (0 to 0)-1.24 (-3.41 to 0.93)0.55 (-1.63 to 2.74)-0.99 (-3.09 to 1.10)-0.26 (-2.39 to 1.87)
SecondaryImproved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-4.3 (-5.97 to -2.56)-5.5 (-7.04 to -3.99)-4.8 (-6.33 to -3.32)-5.9 (-7.37 to -4.45)-4.9 (-6.38 to -3.36)
Difference in means (MM120-placebo)0 (0 to 0)-1.25 (-3.48 to 0.99)-0.55 (-2.77 to 1.67)-1.64 (-3.84 to 0.56)-0.60 (-2.83 to 1.62)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 1
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-2.1 (-4.46 to 0.20)-1.4 (-3.70 to 0.90)-1.9 (-3.54 to -0.16)-3.1 (-5.56 to -0.58)-2.5 (-4.35 to -0.73)
Difference in means (MM120-placebo)0 (0 to 0)0.73 (-2.44 to 3.90)0.28 (-2.52 to 3.08)-0.94 (-4.22 to 2.35)-0.41 (-3.29 to 2.46)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 2
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.0 (-2.83 to 0.83)-2.2 (-4.07 to -0.33)0.4 (-1.33 to 2.18)-2.4 (-4.70 to -0.02)-2.2 (-4.10 to -0.34)
Difference in means (MM120-placebo)0 (0 to 0)-1.20 (-3.74 to 1.34)1.42 (-1.04 to 3.88)-1.36 (-4.22 to 1.50)-1.22 (-3.78 to 1.34)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 4
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from Baseline-3.6 (-6.07 to -1.17)-2.5 (-3.99 to -1.01)-1.1 (-2.72 to 0.51)-3.3 (-5.76 to -0.77)-1.2 (-3.17 to 0.81)
Difference in means (MM120-placebo)0 (0 to 0)1.12 (-1.67 to 3.91)2.51 (-0.34 to 5.37)0.35 (-3.01 to 3.72)2.44 (-0.63 to 5.51)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-4.4 (-7.33 to -1.51)-2.0 (-3.74 to -0.26)-0.7 (-2.29 to 0.88)-1.8 (-4.19 to 0.65)-2.8 (-4.38 to -1.20)
Difference in means (MM120-placebo)0 (0 to 0)2.42 (-0.87 to 5.71)3.72 (0.49 to 6.94)2.65 (-0.97 to 6.27)1.63 (-1.61 to 4.87)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-3.9 (-6.77 to -1.12)-2.7 (-4.83 to -0.55)-1.3 (-3.56 to 0.90)-2.8 (-5.45 to -0.09)-2.7 (-4.38 to -1.05)
Difference in means (MM120-placebo)0 (0 to 0)1.26 (-2.15 to 4.67)2.61 (-0.85 to 6.07)1.18 (-2.54 to 4.89)1.23 (-1.96 to 4.42)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 1
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline0.1 (-1.88 to 2.08)-1.4 (-2.57 to -0.21)-0.6 (-2.88 to 1.63)-1.1 (-2.90 to 0.63)-1.1 (-3.41 to 1.24)
Difference in mean (MM120-placebo)0 (0 to 0)-1.49 (-3.69 to 0.71)-0.73 (-3.56 to 2.11)-1.24 (-3.75 to 1.28)-1.18 (-4.04 to 1.68)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 2
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline0.0 (-2.23 to 2.23)-1.1 (-2.51 to 0.28)-0.5 (-3.06 to 2.13)-1.3 (-2.71 to 0.21)-0.6 (-2.39 to 1.19)
Difference in means (MM120-placebo)0 (0 to 0)-1.12 (-3.63 to 1.39)-0.47 (-3.71 to 2.77)-1.25 (-3.80 to 1.30)-0.60 (-3.28 to 2.08)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 4
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-0.2 (-2.53 to 2.13)-1.3 (-3.17 to 0.50)-0.9 (-3.02 to 1.27)-2.1 (-3.97 to -0.29)-1.6 (-5.33 to 2.06)
Difference in means (MM120-placebo)0 (0 to 0)-1.13 (-3.93 to 1.66)-0.68 (-3.66 to 2.31)-1.93 (-4.75 to 0.89)-1.44 (-5.57 to 2.69)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-1.1 (-6.05 to 3.80)-1.3 (-3.46 to 0.89)-1.4 (-3.07 to 0.27)-2.0 (-3.47 to -0.43)-3.2 (-8.19 to 1.74)
Difference in means (MM120-placebo)0 (0 to 0)-0.16 (-5.29 to 4.97)-0.28 (-5.30 to 4.75)-0.83 (-5.84 to 4.18)-2.10 (-8.48 to 4.29)
SecondaryImproved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males

To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
End of Study (Week 12)
Reported as:
Mean · units on a scale
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
units on a scaleArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Change from baseline-0.3 (-2.73 to 2.23)-1.3 (-2.93 to 0.32)-2.4 (-3.86 to -1.00)-1.9 (-3.21 to -0.59)-2.5 (-6.35 to 1.35)
Difference in means (MM120-placebo)0 (0 to 0)-1.06 (-3.82 to 1.70)-2.18 (-4.86 to 0.51)-1.65 (-4.30 to 1.00)-2.25 (-6.52 to 2.02)
SecondarySummary of Sexual Dysfunction Rates (ASEX), Females, to Week 1

Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 1
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 1
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction1210968
Number of Participants without sexual dysfunction1110111016
SecondarySummary of Sexual Dysfunction Rates (ASEX), Females, to Week 2

Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 2
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 2
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction14714510
Number of Participants without sexual dysfunction11135917
SecondarySummary of Sexual Dysfunction Rates (ASEX), Females, to Week 4

Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 4
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction8611610
Number of Participants without sexual dysfunction131381018
SecondarySummary of Sexual Dysfunction Rates (ASEX), Females, to Week 8

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 8
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction561168
Number of Participants without sexual dysfunction14116816
SecondarySummary of Sexual Dysfunction Rates (ASEX), Females, to Week 12

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
End of Study (Week 12)
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 12
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction641067
Number of Participants without sexual dysfunction12125714
SecondarySummary of Sexual Dysfunction Rates (ASEX), Males, to Week 1

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 1
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 1
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction14323
Number of Participants without sexual dysfunction91413209
SecondarySummary of Sexual Dysfunction Rates (ASEX), Males, to Week 2

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 2
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 2
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction03321
Number of Participants without sexual dysfunction111412229
SecondarySummary of Sexual Dysfunction Rates (ASEX), Males, to Week 4

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 4
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction03410
Number of Participants without sexual dysfunction1012122211
SecondarySummary of Sexual Dysfunction Rates (ASEX), Males, to Week 8

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 8
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction13411
Number of Participants without sexual dysfunction71211208
SecondarySummary of Sexual Dysfunction Rates (ASEX), Males, to Week 12

Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 12
ParticipantsArm 1- PlaceboArm 2- 25 μg MM-120 (LSD D-Tartrate)Arm 3- 50 μg MM-120 (LSD D-Tartrate)Arm 4- 100 μg MM-120 (LSD D-Tartrate)Arm 5- 200 μg MM-120 (LSD D-Tartrate)
Number of Participants with sexual dysfunction13120
Number of Participants without sexual dysfunction710131810

Adverse events

Collected over AE collection will occur from the time informed consent is given until Week 12 (or early discontinuation) and will be recorded at each visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1- Placebo0/39 (0%)0/39 (0%)22/39 (56.4%)
Arm 2- 25 μg MM1200/39 (0%)0/39 (0%)30/39 (76.9%)
Arm 3- 50 μg MM1200/40 (0%)1/40 (2.5%)36/40 (90%)
Arm 4- 100 μg MM1200/40 (0%)0/40 (0%)39/40 (97.5%)
Arm 5- 200 μg MM1200/40 (0%)0/40 (0%)40/40 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120
Panic AttackPsychiatric disorders0/390/391/400/400/40
Most frequent other events
Showing 10 of 67
Most frequent other events
EventArm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120
IllusionPsychiatric disorders3/3912/3918/4025/4030/40
NauseaGastrointestinal disorders3/393/3911/4016/4024/40
HeadachesNervous system disorders9/395/399/4014/4011/40
Euphoric moodPsychiatric disorders1/392/395/4011/406/40
Hallucination, visualPsychiatric disorders1/396/399/409/406/40
HyperhidrosisSkin and subcutaneous tissue disorders0/391/394/409/405/40
MydriasisEye disorders1/391/397/408/404/40
ParaesthesiaNervous system disorders3/392/392/402/408/40
TremorNervous system disorders0/390/393/403/408/40
AmxietyPsychiatric disorders2/394/395/404/406/40

Baseline characteristics

There were 198 participants in the Randomized Set and 198 participants in the Safety Set. Of these, 194 (98.0%) of participants were included in the Full Analysis Set and 183 (92.4%) were included in the Per Protocol Set.

Age, Continuous
Age, Continuous(years)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Mean38.7 ± 12.6638.0 ± 12.0845.3 ± 14.2342.7 ± 14.7942.1 ± 13.5341.3 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Female2620201628110
Male131916241284
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
American Indian or Alaska Native000000
Asian213017
Native Hawaiian or Other Pacific Islander000000
Black or African American6321315
White3033293633161
More than one race010113
Unknown or Not Reported112228
Region of Enrollment
Region of Enrollment(participants)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
United States3939364040194
Baseline HAM-A Total Score
Baseline HAM-A Total Score(units on a scale)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Mean30.3 ± 6.5630.2 ± 6.0530.3 ± 5.7129.3 ± 6.4231.0 ± 6.9830.1 ± 6.44
Baseline MADRS Total Score
Baseline MADRS Total Score(units on a scale)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Mean27.6 ± 9.6925.4 ± 7.5827.7 ± 8.3026.5 ± 7.9928.9 ± 8.3127.2 ± 8.50
Baseline PSQL Global Score
Baseline PSQL Global Score(units on a scale)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Mean10.9 ± 4.1510.7 ± 3.4011.1 ± 3.4311.0 ± 3.4710.1 ± 3.3310.8 ± 3.59
Baseline CGI-S
Baseline CGI-S(units on a scale)Arm 1- PlaceboArm 2- 25 μg MM120Arm 3- 50 μg MM120Arm 4- 100 μg MM120Arm 5- 200 μg MM120Total
Mean4.9 ± 0.614.9 ± 0.754.9 ± 0.624.8 ± 0.755.1 ± 0.734.9 ± 0.70

6 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Irvine Center for Clinical Research
    Irvine, California 92614, United States
  • Kadima Neuropsychiatry Institute
    La Jolla, California 92037, United States
  • Pacific Neuroscience Institute
    Santa Monica, California 90404, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Wholeness Center
    Fort Collins, Colorado 80525, United States
  • Segal Trials
    Lauderhill, Florida 33319, United States
  • CNS Healthcare - Orlando
    Orlando, Florida 32801, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Uptown Research
    Chicago, Illinois 60640, United States
  • Sunstone Therapies
    Rockville, Maryland 20850, United States
  • SISU
    Springfield, Massachusetts 01103, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • GMI - Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Lutheran Hospital - Cleveland Clinic
    Cleveland, Ohio 44113, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • University of Texas Health Houston
    Houston, Texas 77054, United States
  • Cedar Clinical Research
    Draper, Utah 84020, United States
  • Cedar Clinical Research - Murray
    Murray, Utah 84107, United States
  • Woodstock Research Center
    Woodstock, Vermont 05091, United States
09

References and documents

Publications

  • Robison R, Barrow R, Conant C, Foster E, Freedman JM, Jacobsen PL, Jemison J, Karas SM, Karlin DR, Solomon TM, Halperin Wernli M, Fava M. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025 Oct 21;334(15):1358-1372. doi: 10.1001/jama.2025.13481. PubMed 40906494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2023, 13 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 7, 2022
StartActual
Aug 24, 2022
Primary completionActual
Oct 6, 2023
CompletionActual
Nov 27, 2023
Results first posted
Mar 20, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05407064
Lead sponsor
Definium Therapeutics US, Inc.
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Aug 24, 2022
Primary completion
Oct 6, 2023
Completion
Nov 27, 2023
Results posted
Mar 20, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lysergide D-tartrate

Start the discussion